

PREVENTION OF CORONARY ARTERY DISEASE

Assessment of Cardiovascular Risk

Recommendations for the assessment of cardiovascular risk in the adult population is presented in Tables 1 and 2 and Figures 1-6. Several multifactorial risk scores to assess the risk for cardiovascular disease have been used to identify patients at high cardiovascular risk and candidates for preventive therapy. The ESC uses the SCORE (Systematic Coronary Risk Estimation) algorithms (SCORE 2 and SCORE2-OP) (<http://www.heartscore.org>)^{1,2}. The 2019 ACC/AHA guidelines on primary prevention use the Pooled Cohort Equation to estimate the 10-year ASCVD (<https://tools.acc.org/ascvd-risk-estimator-plus/#/calculate/estimate/>)³. These algorithms, as well as those based in the Framingham risk score overestimate the risk.⁴ The 2026 ACC/AHA GL on dyslipidemia recommend use the American Heart Association Predicting Risk of cardiovascular disease EVENTS (PREVENT) equations for 10- and 30-year risk assessment to guide lipid-lowering therapy in primary prevention in adults aged 30 to 79 years (<https://professional.heart.org/en/guidelines-and-statements/prevent-calculator>)⁵. They also recommend use of the “CPR” Model: A) Calculate 10-year ASCVD risk; B) Personalize the estimated risk to the specific patient by considering factors not included in PREVENT-ASCVD equations; and C) possibly Reclassify with selective use of coronary artery calcium (CAC) and Reassess treatment recommendations.⁵ Genetic risk estimate for CAD may also be used to predict sudden cardiac death.⁶ Screening for hyperlipidemia is presented in Table 3.

Prevention of Cardiovascular Disease

General recommendations for primary prevention measures are presented in Tables 4 and 5 and Figures 7-12. The four standard modifiable cardiovascular risk factors (SMuRFs) are hypertension, dyslipidaemia, diabetes mellitus, and smoking. These and body-mass index are the most important modifiable risk factors.⁷ **Hypertension** is discussed in detail in the relevant Chapters.

Lifestyle

Data from the Framingham and CARDIA studies provide evidence for the importance of healthier lifestyle for the primordial prevention of cardiovascular disease.^{8,9} Among persons at high genetic risk, a favorable lifestyle (*avoiding smoking and obesity, regular physical activity and a healthy diet*) is associated with a nearly 50% lower relative risk of coronary artery disease than an unfavorable lifestyle.¹⁰⁻¹⁴ Regular *physical activity* has a protective

effect, regardless of whether physical activity follows a weekend warrior pattern or is spread more evenly throughout the week.¹⁵ However, the value of strenuous exercise is debatable. A U-shaped association between all-cause mortality and dose of jogging has been detected with light and moderate joggers having lower mortality than sedentary nonjoggers, whereas strenuous joggers having a mortality rate not statistically different from that of the sedentary group.¹⁶ Lifelong endurance sport participation (ie Marathon runners) is not associated with a more favourable coronary plaque composition compared to a healthy lifestyle.¹⁷ Extremes of physical exertion may trigger myocardial infarction.¹⁸ Thus, moderate-intensity aerobic (endurance) physical activity for a minimum of 30 minutes on 5 days each week, or vigorous-intensity aerobic PA for a minimum of 20 minutes on 3 days each week, or combinations thereof, is generally recommended.¹⁹ **Smoking** is associated with a substantially increased risk of myocardial infarction that is reduced but not becoming negligible with electronic cigarettes.²⁰ **Dietary** habits are important although their significance and implementation depend on the social environment. **Mediterranean diet** has long-term effects on the gut microbiome composition that modulates the protective association between diet and cardiometabolic risk.²¹ Restriction of calories and, probably, intermittent fasting are cardioprotective.²² Higher **olive oil** consumption is associated with lower risk of total and cause-specific mortality.²³ Replacement of **saturated fat and trans-fats** (mainly hydrogenated oils) with unsaturated fats reduces mortality.²⁴⁻²⁷ The PURE prospective observational study to assess the association of nutrients with cardiovascular disease and mortality collected data on more than 135 000 individuals from 18 countries all over the world, and mainly including middle- and low- income countries, for an average of 7.4 years. Higher fruit, vegetable, and legume consumption (375–500 g/day) was associated with a lower risk of non-cardiovascular, and total mortality.²⁸ High **carbohydrate** intake was associated with higher risk of total mortality, but also higher intake of fats (including saturated fatty acids, monounsaturated fatty acids, and total polyunsaturated fatty acids) and animal protein were each associated with lower mortality.²⁹ In the mainly low- or middle-income populations studied, total fat and types of fat were not associated with cardiovascular disease, whereas saturated fat had an inverse association with stroke.²⁹ **Butter consumption** was low and associated with an increased, but not significant, risk of cardiovascular disease, whereas dairy products were associated with lower mortality and cardiovascular disease, particularly stroke.³⁰ Reducing saturated fatty acid intake and replacing it with carbohydrate has an adverse effect on blood lipids.³¹ **Fish (especially oily)** consumption was beneficial.³² The results of PURE may not be directly applicable to western countries with a higher rate of saturated fat and protein, since there has been evidence for a direct association between **red meat** intake and CVD incidence and mortality, although the magnitude of the association is less strong than that for **processed meat**.^{26,27} In an individual-level data analysis of 29,682 adult participants in

six prospective cohort studies in the USA, higher intake of processed meat, unprocessed red meat, or poultry, but not fish, was significantly associated with a small increased risk of incident CVD, whereas higher intake of processed meat or unprocessed red meat, but not poultry or fish, was significantly associated with a small increased risk of all-cause mortality.³³ In the US Health Professionals Follow-Up Study cohort (1,023,872 person years of follow-up), total, unprocessed, and processed red meat intake were each associated with a modestly higher risk of CHD.³⁴ In a prospective study from UK Biobank, compared with meat-eaters, fish eaters had a lower risk of several cardiovascular outcomes—incident CVD, IHD, MI, stroke, and HF—independent of confounders. **Ultraprocessed** foods (chips, soft drinks, sweets, processed meats, many ready meals, fruit yogurts, many breakfast cereals), are high in saturated fat, added sugars, and sodium, which are already targets for cardiometabolic risk reduction.^{35,36} Eating fish rather than meat or poultry was associated with a lower risk of a range of adverse cardiovascular outcomes, and vegetarians showed only lower risk of CVD incidence.³⁷ The effect of unprocessed meat on the risk of IHD is certainly less than that of processed red meat.^{26,33,38,39} It seems that total red meat intake does not differentially influence blood lipids and apolipoproteins, with the exception of triglycerides, when all comparison diets are analyzed together.⁴⁰ As discussed in Chapter on Epidemiology, the discrepant results are likely heavily contributed to by residual confounding, since it is difficult to distinguish between the effect of dietary cholesterol per se and the effect of dietary patterns high in cholesterol or **saturated fat**,⁴¹ and the impact of dietary approaches on clinical outcomes has so far been inconsistent.⁴² In a prospective cohort study and updated meta-analysis, greater **dietary cholesterol** and **egg** consumption were associated with increased risk of overall and CVD mortality. However, the positive association for egg consumption and CVD risk was significant in US cohorts, there was a marginal positive association in European cohorts, and no association in Asian cohorts.⁴³ Excess **sodium** intake is associated with an increased risk of coronary heart disease and cardiovascular mortality.^{44,45} Low to moderate amounts of **alcohol** (such as no more than 1 to 2 drinks a day), as opposed to heavy drinking, are associated with a reduced risk of coronary artery disease, stroke, sudden death, and possibly heart failure.⁴⁶⁻⁴⁸ In a large cohort study, even low-risk drinking was associated with higher cancer mortality among older adults with health-related or socioeconomic risk factors. However, an attenuation of mortality was observed for wine preference and drinking only during meals.⁴⁹ Moderate wine consumption, 12-35 glasses/month is associated with a significantly reduced cardiovascular risk.⁵⁰ **Caffeine**, studied primarily in the context of coffee, has been shown either to have no relationship or to be associated with a lower risk of coronary artery disease and heart failure.^{51,52} Data on relationships between caffeine and diabetes are not consistent, but habitual coffee consumption has been associated with a lower risk of incident type 2 diabetes.⁵¹ Whereas no clear relationship between caffeine and blood

lipids is evident, unfiltered coffee raises low-density lipoprotein cholesterol.⁵¹ Data are fairly consistent that moderate caffeine consumption, again studied primarily in the setting of coffee consumption, was associated with a lower risk of stroke. Data on high doses of caffeine such as that found in energy drinks are limited and generally suggest cardiovascular harm.⁵¹

Aspirin

Although aspirin is necessary for secondary prevention, its value for primary prevention is controversial, because although effective for preventing CAD, it is also associated with excess haemorrhage and the benefit-risk ratio may be small. Aspirin had been found clearly beneficial in high-risk patients as defined by the Million Heart's initiative,⁵³ in intermediate risk (TIPS-3 trial),⁵⁴ and in patients with elevated Lp(a) levels.⁵⁵ Discontinuation of low-dose aspirin prescribed for primary prevention in the absence of major surgery or bleeding has been associated with a >30% increased risk of cardiovascular events.⁵⁶ However, in other trials (ASCEND, ARRIVE, JAPAD, and, especially, the three ASPREE reports but with several limitations⁵⁷) in both diabetic and nondiabetic patients, produced rather controversial results and a risk of increased gastro-intestinal bleeding.⁵⁸⁻⁶¹ In the most recent meta-analyses, aspirin for primary prevention reduced cardiovascular events, but significantly increased the bleeding risk in most,⁶²⁻⁶⁴ although not all of them.⁶⁵ The 2019 ACC/AHA (2019 GL on Primary Prevention of CVD) considers aspirin 75-100 mg, for primary prevention among select adults 40 to 70 years of age who are at higher ASCVD risk but not at increased bleeding risk (IIb A), and discourages its use in persons aged >70 years.⁶⁶ Similar recommendations (for patients with a 10-year CV risk $\geq 10\%$ and aged 40-59 years but not for those ≥ 60 year)-old) were provided by the 2021 U.S. Preventive Services Task Force (USPSTF) report.⁶⁷ The ESC discourages its use (III A) in patients without cardiovascular disease (ESC 2021 GL on CVD prevention), but gives a IIb A recommendation for high risk patients with diabetes (ESC 2021 GL on CVD Prevention, and 2023v GL on diabetes).^{68,69} Diabetics are at increased risk for CVD, and aspirin may be considered in high-risk, and especially young (<70 years) patients.^{70,71} Individuals with coronary artery calcium (CAC) ≥ 100 and, in particular, CAC ≥ 400 may be good candidates for aspirin therapy for primary prevention.⁷² In adults ≥ 70 years without overt CVD and with an estimated risk of major CVD events <1% per year, aspirin is not indicated.⁷³ Of note, aspirin use 3 or more times per week has been associated with a reduction in all-cause cancer, and especially oesophageal, gastro-intestinal, and colorectal cancer, and mortality,^{74,75} as well as with a significantly lower risk of hepatocellular carcinoma in patients with chronic viral hepatitis.⁷⁶ Thus, an individualized approach should always be adopted.^{58,77} Currently available P2Y₁₂ inhibitors are rather unlikely to replace aspirin, because of unconvincing demonstration of their superiority vs. low-dose aspirin.⁵⁷

Lipid disorders

Screening with a lipid profile should start at the age of 19 years unless if familial hypercholesterolemia is suspected (Table 3). Non-fasting blood samples can be routinely used for the assessment of **plasma lipid profiles**.⁷⁸ Preparative ultracentrifugation represents the gold standard for measuring **LDL-C**, but it is time-consuming and expensive to perform. Thus LDL-C is traditionally estimated by equations such as the Friedewald, or the Martin/Hopkins and Sampson/NIH equations. The last two are preferred by the ACC/AHA 2026 GL on dyslipidemias, but the most commonly used is the Friedewald equation [$\text{LDL-C} = \text{total cholesterol} - \text{HDL-C} - (\text{triglycerides}/5)$], that underestimates LDL when triglycerides are $\geq 150 \text{ mg/dl}$.⁷⁹ LDL-C, therefore, depends on triglyceride measurements, and fasting, defined as 10-12 h of no oral intake other than water or medications, may affect its value. Maximal mean changes for random, non-fasting vs fasting levels are +26 mg/dL for triglycerides and -8 mg/dL for total cholesterol or LDL.⁸⁰ A novel adaptable LDL-C estimation method that uses an adjustable factor instead of 5 in the equation, has been found more accurate in nonfasting individuals by means of approaching direct measures of LDL by rapid ultracentrifugation.⁸¹ If triglycerides are $>200 \text{ mg/dl}$ elimination of sugar and trans fats intake as well as weight reduction and regular exercise may achieve reductions of up to 50%. Tests of apolipoprotein B and A-I, lipoprotein(a), or lipoprotein-associated phospholipase A2 do not add significant improvement in CVD prediction (Table 3).⁸² Recommendations for lifestyle changes are provided in Tables 6 and 13, for medical therapy in Tables 6-13 and Figures 13-24. Specific recommendation for hypertriglyceridemia are presented in tables 10 and 13 and Figures 17-21.

Statins

Statin therapy is associated with a relative risk reduction of 24% for CAD, and this raises to 44% among persons at high genetic risk for CAD.⁸³ Statins inhibit the enzyme HMG-CoA reductase that facilitates the production of cholesterol in the liver, and significantly reduce mortality and cardiovascular events both in patients with established CAD and persons at risk as a primary prevention measure.^{84,85} Guidelines on dyslipidemia (2026 ACC/AHA, 2019 and 2025 ESC) a goal of LDL-C $<70 \text{ mg/dL}$ (1.8 mmol/L) for high-risk patients and LDL-C $<55 \text{ mg/dL}$ (1.4 mmol/L) for secondary prevention in patients at very high risk of ASCVD events.^{1,2,5} Strict LDL-C control with a target of $<70 \text{ mg/dl}$ has been found to significantly attenuate plaque volume progression based on noninvasive quantitative assessment by coronary CTA.⁸⁶ There has also been evidence that patients who achieve an LDL-C level $<50 \text{ mg/dl}$ are at lower cardiovascular disease risk than are those achieving an LDL-C level 75 to $<100 \text{ mg/dl}$, but clear attribution of this to high-dose statin therapy could not be ascertained.⁸⁷ However, the intensity of statin therapy is associated with mortality reduction in patients with cardiovascular disease.⁸⁸ Statin therapy in an intermediate-risk, ethnically diverse population

without cardiovascular disease has also resulted in a significantly lower risk of cardiovascular events (Hope 3).⁸⁹ Thus, cholesterol-lowering therapy is also indicated in patients with diabetes, chronic kidney disease, transplantation, peripheral artery disease, and at risk of stroke. Optimal LDL-C control should be started early in life.⁹⁰ Lipid lowering drugs, with the possible exception of bile acid sequestrants that are not absorbed, should not be given in **pregnancy** or during the **breastfeeding** period.⁹¹

High dose statins increase **Lp(a)** although they reduce the risk of CVD, but PCSK9 inhibitors lower Lp(a).⁹² Many Lp(a)-lowering drugs, including monoclonal antibodies, small interfering ribonucleic acids, antisense oligonucleotides, small molecules, and gene editing compounds, are at different stages of clinical investigation and show promise for clinical use.⁹³⁻⁹⁵ Low **HDL-C** levels can be caused by genetic abnormalities, haematologic malignancies, liver disease, acute inflammatory states and drugs such as anabolic steroids, atypical antipsychotics, antiretroviral therapy, β -blockers, and immunosuppressive agents.⁹⁶ They are treated with life-style changes, since *niacin* or *inhibitors of cholesteryl ester transfer* protein did not improve cardiovascular outcomes despite significantly increasing the HDL cholesterol level.⁹⁷⁻⁹⁹

Statins may be *lipophilic* (lovastatin, simvastatin, atorvastatin, pitavastatin) or *hydrophilic* (pravastatin, rosuvastatin). Hydrophilic statins may have fewer side effects due to less muscle cell penetration and lower dependence on the cytochrome P450 enzyme but differences between the two groups by means of clinical outcomes are not established.¹⁰⁰ Furthermore, lipophilic statins cross the blood-brain barrier and might be protective against neurodegenerative disorders, such as Parkinson disease,¹⁰¹ and may specifically inhibit aldosterone secretion.¹⁰² Rosuvastatin is twice as potent as atorvastatin, but there is considerable individual variation in the LDL-C reduction at all doses statins.¹⁰³ All statins decrease mitochondrial function, attenuate energy production, and alter muscle protein degradation, and may thus produce statin-associated **myopathy**.^{104 105} Statin-associated muscle symptoms and CK levels cover a broader range of clinical presentations, usually with normal or minimally elevated CK levels (< 4 ULN), with a prevalence of 7–29% in registries and observational studies. All statins may result in elevated CK levels but simvastatin has been particularly associated with myopathy.¹⁰⁶ Additional risk factors for myopathy are age (>80 years), female sex, hypothyroidism, diabetes, renal and hepatic function impairment, preexisting myopathies, major surgery, and vitamin D deficiency that by itself can cause musculoskeletal pain.¹⁰⁷ Interruption of statins for 2–6 weeks and resumption of another statin with lower or intermittent doses and ezetimibe may be needed. When it is difficult to determine whether a patient's symptoms are attributable to statin, the “n-of-1 trial” approach may be used, ie the patient is assigned to statin therapy or placebo, up to three times each, for up to three weeks.¹⁰⁸ The possibility of “nocebo effect”, ie exaggeration of symptoms when

the patients and the doctor are aware of statin therapy (as opposed to blinded, randomised trials), should be also considered.¹⁰⁹ Most patients with statin myopathy can continue statin therapy.¹¹⁰ Myopathy with significant elevation of serum creatine kinase (>10 of upper limit of normal-ULN), is a rare but serious side effect of statins, affecting 1 per 10 000 people on standard statin doses. **Mild myalgia** may affect 5-10% of statin users.¹⁰⁵ For **muscle cramps** a switch to another statin might be tried, as well as diltiazem, and vitamin B complex with or without magnesium supplements (see also Chapter 33).¹¹¹ Statin-associated **autoimmune myopathy** is a more serious condition, occurring on 2-3/100,000 patients treated with statins. It is characterized by CK levels >2000 IU/L (ie >10 times the upper normal limit), muscle weakness, evidence of muscle-cell necrosis on biopsy, and the presence of autoantibodies against 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase that establish diagnosis. In contrast to most patients who have side effects from statin therapy, those with statin-associated autoimmune myopathy may have progressive weakness that must be controlled with immunosuppressive therapy.¹¹² **Rhabdomyolysis** with additional renal impairment and/or myoglobinuria is a rare (1/10000) but serious complication of high-dose statin therapy.¹¹³

Mild elevations in **serum aminotransferases** arise in up to 3% of treated patients, usually, but not invariably, without concomitant γ GT elevation, but clinically apparent drug-induced liver injury is rare.¹¹⁴ In the U.S. Drug Induced Liver Injury Network Registry, among 1,188 cases of drug-induced liver injury, 22 cases were attributed to a statin with a latency to onset of 34 days to 10 years (median 155 days) since starting therapy. Nine patients presented with cholestatic hepatitis and 12 patients presented with hepatocellular injury, of which six had an autoimmune phenotype. Nine patients were hospitalized, four developed evidence of hepatic failure, and one with pre-existing alcoholic liver disease died. All commonly used statins were implicated.¹¹⁵ Statin therapy (as well as niacin) is associated with a slightly increased risk of development of **diabetes**, especially in high doses, but the risk is low, approximately one patient per 1000 per year.¹¹⁴ Inhibition of HMG-CoA reductase is associated with increased body-mass index leading to increased insulin resistance, and to increased diabetes,¹¹⁶ and diabetes progression in diabetics.¹¹⁷ The proposed mechanism is that augmented uptake of cholesterol (caused by statins) in pancreatic β cells lowers insulin production. Patients with familial hypercholesterolemia have low incidence of type 2 diabetes mellitus, due to their genetically determined low production of the LDL cholesterol receptor.¹¹⁸ Statins should not be stopped in high-risk primary and secondary prevention patients, but screening of individuals with evidence of metabolic syndrome is reasonable. Pitavastatin has been associated with a lower risk of new-onset diabetes mellitus,¹¹⁹ but it lacks data on cardiovascular outcomes from large trials in patients with diabetes. Rosuvastatin (20 mg od) and atorvastatin (40 mg od) have comparable efficacy for reducing

cardiovascular risk but rosuvastatin results in lower LDL cholesterol levels and a higher risk of new onset diabetes mellitus and cataract.¹²⁰ There is no increased risk of developing cognitive defects such as memory loss.^{114,121} In another retrospective observational analysis of databases, an increased risk of acute kidney injury was found with high potency statins (≥ 10 mg rosuvastatin, ≥ 20 mg atorvastatin, and ≥ 40 mg simvastatin) in the first 120 days after initiation of treatment,¹²² but such a relationship was refuted in a subsequent meta-analysis.¹²³ There is no increased risk of cancer with statins,¹²⁴ and these agents may actually reduce the risk of cancer in heart transplant recipients.¹²⁵ Statins reduce the risk of ischaemic stroke risk,¹²⁶ while an association with intracranial haemorrhage has not been confirmed.¹¹⁴ particularly those cases with a lobar location.¹²⁷ Some worsening in energy and exertional fatigue, especially in women, may be seen.¹²⁸ However, the prevalence of statin intolerance, in general, may be overestimated.¹²⁹ In the **elderly** (≥ 75 years) current guidelines recommendations are less clearly defined. However recent evidence is clearly in favour of therapy even in patients >80 years.¹³⁰⁻¹³⁴ Statins have traditionally been contraindicated during **pregnancy** and lactation due to concerns about their potential risks. However, in a National Norwegian Registry, no association between statin exposure in pregnancy and congenital malformations was detected.¹³⁵

Metabolism of statins occurs through *cytochrome P450* enzymes subcategories such as CYP3A4 (the most common enzyme involved in drug metabolism), and CYP2C9, and several **drug interactions** may occur.¹³⁶ Simvastatin and lovastatin undergo significant CYP3A4 metabolism, whereas atorvastatin undergoes a much lesser amount. Fluvastatin, rosuvastatin and pitavastatin utilize CYP2C9, and pravastatin (a substrate for P-gp) does not undergo CYP450 metabolism. Thus, CYP3A4 inhibitors *ketoconazole*, *posaconazole*, and especially *itraconazole*, *erythromycin*, *clarithromycin*, *telithromycin*, *ciprofloxacin*, *HIV protease inhibitors* (such as *lopinavir*, *ritonavir*, *atazanavir*, *darunavir*, and *fosamprenavir*), and *hepatitis C virus protease inhibitors* (such as *boceprevir* and *telaprevir*), may significantly increase statin, and especially lovastatin and simvastatin exposures, and result in rhabdomyolysis. Concomitant administration of lovastatin and simvastatin with HIV protease inhibitors or HCV protease inhibitors, therefore, is contraindicated (see also www.hiv-druginteractions.org). Atorvastatin should be restricted to 20 mg od, rosuvastatin to 10 mg, and pravastatin does not need dosage modification, whereas no data are available for fluvastatin, in patients taking HIV or HCV protease inhibitors. *Calcium channel blockers*, as well as *dronedarone*, *ranolazine* and *conivaptan* (an IV vasopressin receptor antagonist used for the treatment of euvoletic or hypervolemic hyponatremia), may result in moderate increases in statin exposure, and caution is needed for combinations with lovastatin and simvastatin. High atorvastatin doses (80 mg) may increase digoxin toxicity. Combination therapy of *cyclosporine*, everolimus, tacrolimus or sirolimus with lovastatin, simvastatin and

pitavastatin are potentially harmful. Rosuvastatin, fluvastatin, pravastatin, and atorvastatin may be used but at the lowest doses. In patients taking *colchicine*, lovastatin, simvastatin and atorvastatin should be given at lower doses.¹³⁶

Ezetimibe

Several patient groups may need additional medication.¹³⁷ Ezetimibe is an inhibitor of NPC1L1, a protein that transports dietary cholesterol from the gut into intestinal enterocytes. Mutations that inactivate NPC1L1 have been associated with a reduced risk of CAD,¹³⁸ and compared with atorvastatin monotherapy, the combination of statin plus ezetimibe results in greater coronary plaque regression.¹³⁹ In the large IMPROVE-IT trial, adding ezetimibe to statin therapy in patients with an acute coronary event decreased the risk of MI and stroke by 1-2% without affecting cardiovascular mortality,¹⁴⁰ and with a particularly large effect seen in patients with a prior stroke.¹⁴¹ The clinical benefit following an acute event appears to be enhanced in patients with a prior CABG.¹⁴² In the EWTOPIA 75 trial ezetimibe prevented cardiovascular events in individuals aged ≥ 75 years with elevated LDL-C levels, supporting the importance of primary prevention in this age group.¹⁴³

Fibrates

Fibrates added to statin have not been found to reduce cardiovascular events (ACCORD and PROMINENT RCTs).^{144,145} Fibrates reduce triglyceride levels and increase HDL, but by stimulating lipoprotein lipase they result in increased levels of LDL and apolipoprotein B. According to new guidelines by the AHA, treatment with fibrates is indicated only for triglyceride levels >500 mg/dL.¹⁴⁶ The combination (especially with gemfibrosil) increases the risk of myopathy and fibrates increase homocysteine levels that may be prothrombotic; in addition, the ability of fibrates to increase HDL may be attenuated in patients with type-2 diabetes. Combinations of a statin with a fibrate (apart from gemfibrosil) might still be considered in high risk individuals such as diabetics with a high triglyceride/low HDL-C pattern.¹⁴⁷ New fibrates, such as pemafibrate, are in study.¹⁴⁸

Omega-3 fatty acids

The omega-3 fatty acids (n-3 FAs) eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) at a dose of EPA+DHA or EPA-only at a dose of 3-4 g/d are now recommended by both AHA and ESC for reducing triglycerides as monotherapy or as an adjunct to other lipid-lowering agents.^{91,149} However, the evidence is to some extent controversial. No established benefit of capsule supplementation of a mixture of omega-3 fatty acids was found in a previous meta-analysis,¹⁵⁰ and three subsequent RCTs (ASCEND, VITAL and STRENGTH trials).¹⁵¹⁻¹⁵³ No reduction in clinical events in elderly patients with recent MI who were treated with 1.8 g n-3 PUFAs daily for 2 years was seen in the OMEMI RCT.¹⁵⁴ In the REDUCE-IT RCT, the EPA icosapent ethyl (2g bd) was shown to reduce the risk of ischaemic events and cardiovascular death in patients with established cardiovascular disease

or with diabetes and other risk factors, who had been receiving statin therapy and who had a fasting triglyceride level 135 - 499 mg/dL.¹⁵⁵ Risk reduction was observed across a range of Lp(a) levels,¹⁵⁶ and a reduction in plaque volume was also detected.¹⁵⁷ In patients with a history of coronary artery bypass grafting, treatment with icosapent ethyl was associated with significant reductions in first and recurrent ischemic events.¹⁵⁸ In a meta-analysis, triglyceride lowering was associated with a lower risk of major vascular events, even after adjustment for LDL-C lowering, although the effect is less than that for LDL-C and attenuated when REDUCE-IT was excluded.¹⁵⁹ The different results of the STRENGTH and REDUCE-IT have been attributed to the atherogenic mineral oils (STRENGTH) vs the corn oils (REDUCE-IT) that were used as comparator oils.¹⁶⁰ In the RESPECT-EPA RCT, icosapent ethyl treatment resulted in a numerically lower risk of cardiovascular events that did not, however, reach statistical significance in patients with chronic coronary artery disease.¹⁶¹ Thus, supplementation of EPA should be recommended in these patients,¹⁶² but at an increased risk of AF, since marine omega-3 fatty acid supplementation (especially >1g/day) is associated with a significant increased risk of AF.^{163,164} Recommendations are provided in Table 8.

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors

Monoclonal antibodies

Alirocumab and *evolocumab* are monoclonal antibodies that significantly reduce LDL and Lp(a) levels, given alone or in combination with statins. In patients not responding or intolerant to high-intensity statins and ezetimibe, alirocumab 75-150 mg subcutaneously every two weeks, or evolocumab 140 mg subcutaneously every two weeks or 420 mg monthly, reduced the atheroma volume and cardiovascular events by reducing both LDL-C and hsCRP (FOURIER and ODYSSEY trials).^{165,166} The addition of alirocumab to high-intensity statin therapy has also resulted in regression of coronary plaque burden and plaque stabilization in patients with familial hypercholesterolemia (PACMAN-AMI and ARCHITECT trials).^{167,168} In patients with atherosclerosis or diabetes and without a previous myocardial infarction or stroke but with an LDL $\geq$ 90 mg/dL, evolocumab led to a lower risk of first cardiovascular events (VESALIUS-CV RCT).¹⁶⁹ The effect of PCSK9 inhibitors depends on residual LDL receptor activity, and side effects are similar to those of statins, without increased risk of diabetes as initially observed.¹⁷⁰ However, when LDL levels <25 mg/dL are achieved there is an increased risk of cataracts and neurocognitive effects,^{171,172} although the latter has not been verified in all trials.¹⁷³ Concerns have emerged for high immunogenicity with antidrug-antibody formation for agents such as bococizumab,¹⁷⁴ and, to a much lesser degree, alirocumab.¹⁷⁵ Antidrug PCSK9 inhibitor antibodies in post-treatment samples was seen in up to 2.5% of patients on inclisiran but were often transient and not associated with changes in any pharmacologic or clinical

measurements. Injection-site adverse events occurred in 2-4% of patients but were mild.^{176,177} The FDA approved alirocumab and evolocuman for secondary prevention in high-risk patients who cannot control their cholesterol with statins in 2015, and both ACC and ESC recommend their use in statin-treated high-risk patients who cannot achieve a LDL-C <70 mg/dL.^{178,179} Other monoclonal antibodies are also effective.¹⁸⁰ Enlicotide is an oral PSK9 inhibitor with a very good efficacy and safety profile in patients with heterozygous familial hypercholesterolaemia.¹⁸¹ In statin-treated adults with a history of a major ASCVD event or at increased risk for a first event, enlicotide achieved greater reductions in LDL-C, ApoB, and non-HDL-C than ezetimibe or bempedoic acid.¹⁸² Laroprovast is a small-molecule proprotein convertase subtilisin/kexin type 9 inhibitor that does not block the proprotein convertase subtilisin/kexin type 9–LDL receptor interaction but stabilizes the proprotein convertase subtilisin/kexin type 9 C-terminal domain and prevents lysosomal trafficking and degradation of the LDL receptor. Laroprovast and rosuvastatin treatment lowers LDL levels by 80%.¹⁸³

RNA interference (RNAi) inhibitors

These are nucleic acid therapies that catalytically degrade PCSK9 mRNA.

Inclisiran (also FDA-approved) can be given with an infrequent dosing regimen, ie 300 mg SC injection repeated in 3, 9 and 15 months or just twice a year (ORION trials).^{176,177,184} Main side-effects are injection-site reactions and pain in 10% of patients.^{184,185} Interestingly, however, in patients with homozygous familial hypercholesterolemia, inclisiran treatment did not reduce LDL-C levels despite substantial lowering of PCSK9 levels.¹⁸⁶ This finding could be explained, at least in part, by the fact that LDLR is completely lacking or defective in patients with HoFH. In such circumstances, even complete elimination of PCSK9, a target of inclisiran, does not influence the impaired clearance of LDL-C.¹⁸⁷ *Olezarsen*, an antisense oligonucleotide targeting messenger RNA for apolipoprotein C-III (APOC3) has also shown promising results in reducing triglyceride levels and reducing the risk of pancreatitis in patients with fasting triglyceride levels >500 mg /dL.^{188,189}

ATP-citrate lyase inhibitors

Bempedoic acid is an oral small molecule that inhibits cholesterol synthesis by inhibiting the action of ATP-citrate lyase, a cytosolic enzyme upstream of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase pathway.¹⁹⁰ Bempedoic acid (single dose 180 mg/day) reduces LDL-C levels by approximately 23% as monotherapy, approximately 18% when given on a background of statin therapy, and by 38% when given in a fixed-dose combination with ezetimibe.^{191,192} Among statin-intolerant patients, treatment with bempedoic acid was associated with a lower risk of major adverse cardiovascular events (death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization) (CLEAR RCT). The incidences of gout and cholelithiasis were higher with bempedoic acid than with placebo, as were the incidences of small increases in serum

creatinine, uric acid, and hepatic-enzyme levels.¹⁹¹ In the BempedACS RCT, adding bempedoic acid to statin–ezetimibe therapy in the setting of ACS was safe but failed to improve the percentage of patients achieving the LDL-C goal (<55 mg/dL) at 8 weeks.¹⁹³

Angiopoietin-like 3 (ANGPTL3) inhibitors

ANGPTL3 is a hepatic protein involved in the regulation of lipoprotein metabolism and homeostasis. SHR-1918 is a long-acting, fully-human, monoclonal antibody directed against ANGPTL3 is a new promising approach.¹⁹⁴

Cholesteryl ester transfer protein inhibitors

Cholesteryl ester transfer protein (CETP) facilitates the exchange of cholesteryl esters and triglycerides between HDL particles and atherogenic particles containing apolipoprotein B in the blood. However, trials of various CETP inhibitors, with one exception studying anacetrapib,¹⁹⁵ have shown neutral or adverse effects on cardiovascular outcomes. In a pooled analysis of trials, obicetrapib a highly selective CETP inhibitor, resulted in reductions in circulating concentrations of Lp(a).¹⁹⁶

Current tools of human genetics may also be of help by estimating the effects of modifying therapeutic targets. Genetic variants that mimic the effect of ATP citrate lyase inhibitors and statins have been shown to reduce LDL levels and cardiovascular risk by the same mechanism of action.¹⁹⁰ Genetic (polygenic) risk scores are also useful for identifying patients for whom PCSK9 therapy is justified.^{197,198}

Severe Hypercholesterolemia (LDL-C $\geq$ 190 mg/dL [4.9 mmol/L])

Specific therapy of *familial hypercholesterolaemia* is presented in Figure 8, and Table 8. Patients with homozygous familial hypercholesterolemia, and severe forms of heterozygous familial hypercholesterolemia may not respond to conventional therapy, and nucleic acid therapies such as PCSK9 inhibitors and small interfering RNA may be required.¹⁸⁷ Evinacumab, a monoclonal antibody against ANGPTL3, has also shown potential benefit in patients with homozygous familial hypercholesterolemia.¹⁹⁹ Recent advances in DNA- and RNA-based therapeutics are making gene-based therapy for FH an alternative approach for treatment of FH.¹⁸⁷

Specific recommendations for statin therapy Racial/Ethnic Issues in evaluation, and Treatment of CVD risk in Asian Americans, Hispanic/Latino Americans, and Blacks have been provided by the AHA/ACC 2018 GL on cholesterol.

Diabetes Mellitus

Ideally, and especially in young patients, preprandial and postprandial glucose should be maintained at <130 mg/dl and <180 mg/dl, respectively.²⁰⁰ Intensive glycemic control reduces risk for cardiovascular disease events, although the effect appears modest in comparison to

the cardiovascular benefits from lipid and blood pressure management. Along with lifestyle recommendations, the standard initial pharmacologic treatment used in patients with type 2 diabetes is **metformin**. Addition of a glucose-lowering medication with demonstrated cardiovascular benefit, including specific agents from the **glucagon-like peptide-1 (GLP-1) receptor agonist** especially in obese patients or **sodium-glucose cotransporter type 2 (SGLT2) inhibitor** classes especially in patients with heart failure and reduced ejection fraction or kidney disease, is also recommended.^{71,201,202} GLP-1RA receptor agonists and SGLT2 inhibitors are now recommended to improve cardiovascular outcomes in patients with high cardiovascular risk, regardless of HbA1c.^{71,203,204} SGLT2 inhibitors are most effective if the estimated glomerular filtration rate is more than 60 ml/min/1.73m² at initiation, and should be avoided where there is a risk of diabetic ketoacidosis. GLP-1 receptor agonists are contraindicated in those with a history of medullary thyroid cancer and used with caution in patients with a history of pancreatitis of a known cause.²⁰⁵

Metformin (a biguanide) has a low side-effect profile and proven efficacy for cardiovascular risk and total mortality reduction (UKPDS).²⁰⁶ It is associated with weight loss and fewer hypoglycemic episodes, and decreased mortality compared to sulfonylureas, and is considered first-line therapy.²⁰⁷⁻²⁰⁹ There has also been evidence that patients with IHD may benefit from metformin irrespective from diabetic status.²¹⁰ In a post hoc analysis of the SAVOR-TIMI 53, metformin use was associated with lower rates of all-cause mortality although not with lower rates of the composite end point of cardiovascular death, MI, or ischemic stroke.²¹¹ A relevant meta-analysis was also inconclusive.²⁰¹ It is contraindicated in patients with GFR ≤ 30 mL/min/1.73 m², advanced liver disease and any condition that might lead to lactic acidosis.

Inhibitors of sodium-glucose cotransporter 2 (SGLT2-gliflozins), such as **empagliflozin** (10 or 25 mg od), **canagliflozin** (100-300 mg od), **dapagliflozin** (10 mg od), **ertugliflozin** (5-15 mg od), and **sotagliflozin** (200-400 mg od) reduce filtered glucose reabsorption in the proximal renal tubule, leading to glucosuria. They have been shown to significantly reduce heart failure, progression of kidney disease, and cardiovascular mortality in patients with HFrEF (EMP-REG trials, CANVAS program, DECLARE-TIMI 58, CREDENCE, DAPA-HF, EMPEROR-Reduce, VERTIS CV and SOLOIST-WHF trials), via various mechanisms.²¹²⁻²¹⁹ SGLT2 inhibitors are considered first-choice drugs for patients with CVD, renal disease (but with eGFR ≥ 30 ml/min/1.73 m²) or heart failure.²⁰⁹ Dapagliflozin also appears to lower the risk of AF/AFL in patients with type 2 diabetes mellitus, including those with and without coronary artery disease or heart failure.²²⁰ However, a reduction in total and cardiovascular mortality was seen only in the EMP-REG trial.²²¹ They are FDA-approved agents but due to resultant increased glycosuria they should be used with caution in patients with poor urinary hygiene, especially in those with prior

mycotic genital infections.²²² FDA warnings have emerged due to increased risk of renal injury and fractures and leg and foot amputations with the SGLT2 *canagliflozin*,²²³ and cases of Fournier gangrene, a rare urologic emergency characterized by necrotizing infection of the external genitalia, perineum, and perianal region with SGLT2 inhibitors in general.²²⁴ These complications are very rare, and although studies have detected reduced bone mineral density at the hip, meta-analyses of clinical trials have not shown increased hip fracture risk with the use of SGLT2 inhibitors.⁷¹ However, the drugs should be avoided in patients with such history, as well as history of diabetic ketoacidosis, or when the patient is considering pregnancy or is breast feeding.

SGLT2 inhibitors with the additional capacity of **SGLT1 inhibition**, such as *sotagliflozin*, may be even more efficacious in inhibitors in lowering hemoglobin A1C levels in patients with chronic kidney disease and preventing downstream microvascular complications of type 2 diabetes.²²⁵ SGLT2 is of primary importance for glucose reabsorption from the urinary filtrate, whereas SGLT1 is responsible for glucose absorption in the small intestine and the distal proximal tubule. SGLT1 inhibition reduces glucose and hemoglobin A1C levels in patients with an estimated glomerular filtration rate $< 30 \text{ mL}/(\text{min} \cdot 1.72 \text{ m}^2)$ to a similar degree as in those with an estimated glomerular filtration rate $\geq 30 \text{ mL}/(\text{min} \cdot 1.72 \text{ m}^2)$. Thus, a relative increase in SGLT1 inhibition, such as that occurring with sotagliflozin, may have an advantage compared with currently available SGLT2.

Incretin-based therapies potentiate the glucagon-like peptide-1 (GLP-1) action through selective **GLP-1 receptor (GLP-1RA)** agonism or by prevention of enzymatic degradation by inhibition of **dipeptidyl peptidase 4 (DPP-4)**, and thus enhance insulin secretion, inhibit glucagon release, and decrease gastric emptying to slow glucose absorption.^{226,227} The **GLP-1 receptor agonists** are administered as daily (*liraglutide*, *lixisenatide*) or once weekly (*albiglutide*, *dulaglutide*, *efpeglenatide*, *exenatide*, and *semaglutide*) injections. *Semaglutide* is also available for oral administration. They have been shown to lower body weight, and decrease cardiovascular events, adverse renal outcomes, and cardiovascular mortality.^{209,228,229} *Liraglutide*, in combination with metformin, appears to be the most effective agent (LEADER,²³⁰ and GRADE RCTs²³¹). It reduces cardiovascular events significantly higher than other agents such as sitagliptin or glimepiride.²³²

Although tirzepatide benefits patients with HF with preserved ejection fraction,²³³ there has been no evidence of clear benefit on HF-related outcomes and there is even uncertainty regarding the safety in those with HF with reduced ejection fraction.²³⁴ They are avoided in persistent nausea, history of gastroparesis, gallbladder disease, history of MEN 2 or proliferative retinopathy (caution with semaglutide or dulaglutide), and pregnancy or breast feeding.²⁰² Liraglutide (up to 1.8 mg SC daily) is also suitable for patients with a history of NYHA functional class I to III HF.²³⁵ In patients with preexisting cardiovascular disease and

overweight or obesity but without diabetes, weekly subcutaneous semaglutide at a dose of 2.4 mg was also superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke at a mean follow-up of 39.8 months.²³⁶ Major concerns regarding pancreatitis, pancreatic cancer, and medullary thyroid cancer have not panned out in meta-analyses of clinical trials. Retinopathy occurred at a higher rate with semaglutide.⁷¹ **Tirzepatide** is a GLP-1 receptor agonist that is also an analogue of the Gastric Inhibitory Polypeptide (GIP) that stimulates the release of insulin from the pancreas. It is more effective than semaglutide for weight loss.²³⁷ The **DPP-4 inhibitors saxagliptin, alogliptin and sitagliptin** do not affect adverse cardiovascular events.^{209,238} The rate of hospitalization for heart failure may be increased with these agents, mainly saxagliptin, with the magnitude of risk dependent on the method of glucose lowering and, potentially, weight gain,^{226,239} although not all reports have verified this finding.²⁴⁰⁻²⁴¹ In a recent real-world study including >30 000 patients with type 2 diabetes, GLP-1RA use was associated with a lower risk of heart failure compared with DPP-4i and similar risks compared with SGLT-2i in routine clinical care.²⁴² Glycemic control with **insulin** may also reduce cardiovascular risk,^{206,231} but early addition of insulin confers no benefit in patients with prediabetes (for definition see Chapter 25) or patients whose type 2 diabetes is well controlled on diet or medication.^{203,243} Insulin therapy leads to increased fluid retention, and body weight gain, and is associated with greater hypoglycaemia risks.²³⁸

Sulfonylureas are associated with increased risk of hypoglycaemia and weight gain, and most of them, especially *chlopropamide* and *tolbutamide*, may increase the risk of cardiovascular events,²³⁸ and in April 2016 the FDA issued a warning regarding this risk. However, the risk is considered low, especially for *gliclazide* and *glimepiride*,²⁴⁴ and the American College of Physicians still allows their use.²⁰⁷ **Thiazolidinediones** may increase the risk of heart failure and should not be used in the presence of impaired LV function. *Pioglitazone* is safer than *rosiglitazone* in this respect,^{245,246} and achieves greater increases in HDL and reductions in glycated hemoglobin, and triglycerides, compared to *glimepiride* with a resultant slower progression of atherosclerosis.²⁴⁷ Among patients with insulin resistance without diabetes mellitus, *pioglitazone* has reduced the risk for acute coronary syndromes after a recent cerebrovascular event.²⁴⁸ Concerns about association with bladder cancer have emerged,²⁴⁹ although this is debatable.²⁵⁰ *Rosiglitazone* has also been associated with a significant increase in the risk of myocardial infarction, although not cardiovascular mortality, in patients with type 2 diabetes mellitus.²⁵¹ However, an analysis of the BARI 2D trial did not detect an association of *rosiglitazone* treatment with an increase in major ischemic cardiovascular events among patients with type 2 diabetes and established coronary artery disease.²⁵² Thiazolidinediones may also increase the risk of long bone fractures and weight gain.²⁰⁷ **Acarbose**, an alpha-glucosidase inhibitor that blocks the absorption of carbohydrate

has been demonstrated to delay diabetes mellitus but its effect on major cardiovascular effects is not proven.²⁵³

Prevention in diabetes mellitus is presented in Tables 14-16, and Figures 25-35.

Chronic Kidney Disease

GFR <60 mL/min/1.73 m² or urine albumin-to-creatinine ratio (uACR) ≥3 mg/mmol (≥30 mg/g) are most commonly used as indicators of kidney disease. The simplest method to estimate GFR is using blood creatinine and a validated estimated GFR (eGFR) equation. The 2009 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) eGFR equation without the race coefficient appears to be an optimal compromise for European populations, instead of the newer 2021 equation that was developed for a US population and overestimates GFR in large parts of Europe.²⁵⁴ Recommendations are presented in Figures 36-38, and Tables 17-20.

Patients on cancer therapy

Recommendations are presented in Tables 8 and 13.

Exercise

Recommendations of exercise in individuals at risk of CAD are presented in Table 21.

References

1. MacDougall DE, et al. Lipoprotein(a) and recurrent atherosclerotic cardiovascular events: the US Family Heart Database. *Eur Heart J*. 2025;46:4762-4775. doi: 10.1093/eurheartj/ehaf297
2. Mach F, et al. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. *Eur Heart J*. 2025. doi: 10.1093/eurheartj/ehaf190
3. Arnett DK, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol*. 2019;74:1376-1414. doi: 10.1016/j.jacc.2019.03.009
4. Lloyd-Jones DM. The Pooled Cohort Equations and the Test of Time. *J Am Coll Cardiol*. 2023;82:1509-1511. doi: 10.1016/j.jacc.2023.08.024
5. Writing Committee M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*. 2026. doi: 10.1161/CIR.0000000000001423
6. Hernesniemi JA, et al. Predicting sudden cardiac death using common genetic risk variants for coronary artery disease. *Eur Heart J*. 2015;36:1669-1675. doi: 10.1093/eurheartj/ehv106
7. Global Cardiovascular Risk C, et al. Global Effect of Modifiable Risk Factors on Cardiovascular Disease and Mortality. *N Engl J Med*. 2023. doi: 10.1056/NEJMoa2206916
8. Xanthakis V, et al. Ideal cardiovascular health: associations with biomarkers and subclinical disease and impact on incidence of cardiovascular disease in the Framingham Offspring Study. *Circulation*. 2014;130:1676-1683. doi: 10.1161/CIRCULATIONAHA.114.009273
9. Spring B, et al. Healthy lifestyle change and subclinical atherosclerosis in young adults: Coronary Artery Risk Development in Young Adults (CARDIA) study. *Circulation*. 2014;130:10-17. doi: 10.1161/CIRCULATIONAHA.113.005445
10. Amit V. Khera, et al. Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease. *NEJM*. 2016. doi: DOI: 10.1056/NEJMoa1605086
11. Estruch R, et al. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts. *N Engl J Med*. 2018. doi: 10.1056/NEJMoa1800389
12. Gupta R, et al. Primary prevention of ischaemic heart disease: populations, individuals, and health professionals. *Lancet*. 2019;394:685-696. doi: 10.1016/S0140-6736(19)31893-8
13. Powell-Wiley TM, et al. Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. *Circulation*. 2021;143:e984-e1010. doi: 10.1161/CIR.0000000000000973
14. Rajagopalan S, et al. Air pollution exposure and cardiometabolic risk. *The lancet Diabetes & endocrinology*. 2024;12:196-208. doi: 10.1016/S2213-8587(23)00361-3
15. Kany S, et al. Associations of "Weekend Warrior" Physical Activity With Incident Disease and Cardiometabolic Health. *Circulation*. 2024;150:1236-1247. doi: 10.1161/CIRCULATIONAHA.124.068669
16. Schnohr P, et al. Dose of jogging and long-term mortality: the Copenhagen City Heart Study. *J Am Coll Cardiol*. 2015;65:411-419. doi: 10.1016/j.jacc.2014.11.023
17. De Bosscher R, et al. Lifelong endurance exercise and its relation with coronary atherosclerosis. *Eur Heart J*. 2023;44:2388-2399. doi: 10.1093/eurheartj/ehad152
18. Smyth A, et al. Physical Activity and Anger or Emotional Upset as Triggers of Acute Myocardial Infarction: The INTERHEART Study. *Circulation*. 2016;134:1059-1067. doi: 10.1161/CIRCULATIONAHA.116.023142
19. Franklin BA, et al. Exercise-Related Acute Cardiovascular Events and Potential Deleterious Adaptations Following Long-Term Exercise Training: Placing the Risks Into Perspective-An Update: A Scientific Statement From the American Heart Association. *Circulation*. 2020;141:e705-e736. doi: 10.1161/CIR.0000000000000749
20. George J, et al. Cardiovascular Effects of Switching From Tobacco Cigarettes to Electronic Cigarettes. *JACC*. 2019.
21. Wang DD, et al. The gut microbiome modulates the protective association between a Mediterranean diet and cardiometabolic disease risk. *Nat Med*. 2021;27:333-343. doi: 10.1038/s41591-020-01223-3
22. de Cabo R, et al. Effects of Intermittent Fasting on Health, Aging, and Disease. *NEJM*. 2019. doi: 10.1056/NEJMra1905136
23. Guasch-Ferré M, et al. Consumption of Olive Oil and Risk of Total and Cause-Specific Mortality Among U.S. Adults. *JACC*. 2022.
24. Wang DD, et al. Association of Specific Dietary Fats With Total and Cause-Specific Mortality. *JAMA Intern Med*. 2016;176:1134-1145. doi: 10.1001/jamainternmed.2016.2417
25. Guasch-Ferré M, et al. Olive Oil Consumption and Cardiovascular Risk in U.S. Adults. *JACC*. 2020.

26. Lichtenstein AH, et al. 2021 Dietary Guidance to Improve Cardiovascular Health: A Scientific Statement From the American Heart Association. *Circulation*. 2021;CIR0000000000001031. doi: 10.1161/CIR.0000000000001031
27. Lichtenstein AH, et al. 2026 Dietary Guidance to Improve Cardiovascular Health: A Scientific Statement From the American Heart Association. *Circulation*. 2026. doi: 10.1161/CIR.0000000000001435
28. Miller V, et al. Fruit, vegetable, and legume intake, and cardiovascular disease and deaths in 18 countries (PURE): a prospective cohort study. *The Lancet*. 2017. doi: 10.1016/S0140-6736(17)32253-5
29. Dehghan M, et al. Associations of fats and carbohydrate intake with cardiovascular disease and mortality in 18 countries from five continents (PURE): a prospective cohort study. *The Lancet*. 2017. doi: 10.1016/S0140-6736(17)32252-3
30. Dehghan M, et al. Association of dairy intake with cardiovascular disease and mortality in 21 countries from five continents (PURE): a prospective cohort study. *Lancet*. 2018. doi: 10.1016/S0140-6736(18)31812-9
31. Mente A, et al. Association of dietary nutrients with blood lipids and blood pressure in 18 countries: a cross-sectional analysis from the PURE study. *Lancet Diabetes Endocrinol*. 2017. doi: 10.1016/S2213-8587(17)30283-8
32. Mohan D, et al. Associations of Fish Consumption With Risk of Cardiovascular Disease and Mortality Among Individuals With or Without Vascular Disease From 58 Countries. *JAMA Intern Med*. 2021. doi: 10.1001/jamainternmed.2021.0036
33. Zhong VW, et al. Associations of Processed Meat, Unprocessed Red Meat, Poultry, or Fish Intake With Incident Cardiovascular Disease and All-Cause Mortality. *JAMA Intern Med*. 2020. doi: 10.1001/jamainternmed.2019.6969
34. Al-Shaar L, et al. Red meat intake and risk of coronary heart disease among US men: prospective cohort study. *BMJ*. 2020;371:m4141. doi: 10.1136/bmj.m4141
35. Vadiveloo MK, et al. Ultraprocessed Foods and Their Association With Cardiometabolic Health: Evidence, Gaps, and Opportunities: A Science Advisory From the American Heart Association. *Circulation*. 2025;152:e245-e263. doi: 10.1161/CIR.0000000000001365
36. Guasti L, et al. Ultra-processed foods, lifestyle management, and cardiovascular diseases. *Eur Heart J*. 2026;47:3456-3473. doi: 10.1093/eurheartj/ehag226
37. Petermann-Rocha F, et al. Vegetarians, fish, poultry, and meat-eaters: who has higher risk of cardiovascular disease incidence and mortality? A prospective study from UK Biobank. *Eur Heart J*. 2021;42:1136-1143. doi: 10.1093/eurheartj/ehaa939
38. Abete I, et al. Association between total, processed, red and white meat consumption and all-cause, CVD and IHD mortality: a meta-analysis of cohort studies. *Br J Nutr*. 2014;112:762-775. doi: 10.1017/S000711451400124X
39. Astrup A, et al. Saturated Fats and Health: A Reassessment and Proposal for Food-Based Recommendations: JACC State-of-the-Art Review. *J Am Coll Cardiol*. 2020;76:844-857. doi: 10.1016/j.jacc.2020.05.077
40. Guasch-Ferre M, et al. Meta-Analysis of Randomized Controlled Trials of Red Meat Consumption in Comparison With Various Comparison Diets on Cardiovascular Risk Factors. *Circulation*. 2019;139:1828-1845. doi: 10.1161/CIRCULATIONAHA.118.035225
41. Carson JAS, et al. Dietary Cholesterol and Cardiovascular Risk: A Science Advisory From the American Heart Association. *Circulation*. 2019;CIR0000000000000743. doi: 10.1161/CIR.0000000000000743
42. Seligman HK, et al. A Systematic Review of "Food Is Medicine" Randomized Controlled Trials for Noncommunicable Disease in the United States: A Scientific Statement From the American Heart Association. *Circulation*. 2025. doi: 10.1161/CIR.0000000000001343
43. Zhao B, et al. Associations of Dietary Cholesterol, Serum Cholesterol, and Egg Consumption With Overall and Cause-Specific Mortality, and Systematic Review and Updated Meta-Analysis. *Circulation*. 2022. doi: 10.1161/CIRCULATIONAHA.121.057642
44. Wang YJ, et al. Dietary Sodium Intake and Risk of Cardiovascular Disease: A Systematic Review and Dose-Response Meta-Analysis. *Nutrients*. 2020;12. doi: 10.3390/nu12102934
45. Ma Y, et al. 24-Hour Urinary Sodium and Potassium Excretion and Cardiovascular Risk. *N Engl J Med*. 2021. doi: 10.1056/NEJMoa2109794
46. Whitman IR, et al. Alcohol Abuse and Cardiac Disease *J Am Coll Cardiol*. 2017;69:13-24. doi: 10.1016/j.jacc.2016.10.048
47. Xi B, et al. Relationship of Alcohol Consumption to All-Cause, Cardiovascular, and Cancer-Related Mortality in U.S. Adults. *J Am Coll Cardiol*. 2017;70:913-922. doi: 10.1016/j.jacc.2017.06.054
48. Piano MR, et al. Alcohol Use and Cardiovascular Disease: A Scientific Statement From the American Heart Association. *Circulation*. 2025. doi: 10.1161/CIR.0000000000001341
49. Ortola R, et al. Alcohol Consumption Patterns and Mortality Among Older Adults With Health-Related or Socioeconomic Risk Factors. *JAMA Netw Open*. 2024;7:e2424495. doi: 10.1001/jamanetworkopen.2024.24495
50. Dominguez-Lopez I, et al. Urinary tartaric acid as a biomarker of wine consumption and cardiovascular risk: the PREDIMED trial. *Eur Heart J*. 2025;46:161-172. doi: 10.1093/eurheartj/ehae804
51. Marcus GM, et al. Caffeine and Cardiovascular Disease: A Scientific Statement From the American Heart Association. *Circulation*. 2026;154:e345-e355. doi: 10.1161/CIR.0000000000001454

52. Chieng D, et al. The impact of coffee subtypes on incident cardiovascular disease, arrhythmias, and mortality: long-term outcomes from the UK Biobank. *Eur J Prev Cardiol.* 2022.
53. Karmali KN, et al. Drugs for Primary Prevention of Atherosclerotic Cardiovascular Disease: An Overview of Systematic Reviews. *JAMA cardiology.* 2016;1:341-349. doi: 10.1001/jamacardio.2016.0218
54. Yusuf S, et al. Polypill with or without Aspirin in Persons without Cardiovascular Disease. *N Engl J Med.* 2020. doi: 10.1056/NEJMoa2028220
55. Lacaze P, et al. Aspirin for Primary Prevention of Cardiovascular Events in Relation to Lipoprotein(a) Genotypes. *JACC.* 2022.
56. Sundstrom J, et al. Low-Dose Aspirin Discontinuation and Risk of Cardiovascular Events: A Swedish Nationwide, Population-Based Cohort Study. *Circulation.* 2017;136:1183-1192. doi: 10.1161/CIRCULATIONAHA.117.028321
57. Patrono C. Low-dose aspirin for the prevention of atherosclerotic cardiovascular disease. *Eur Heart J.* 2024;45:2362-2376. doi: 10.1093/eurheartj/ehae324
58. Ridker PM. Should Aspirin Be Used for Primary Prevention in the Post-Statin Era? *N Engl J Med.* 2018;379:1572-1574. doi: 10.1056/NEJMe1812000
59. Group ASC. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. *N Engl J Med.* 2018. doi: 10.1056/NEJMoa1804988
60. Gaziano JM, et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. *Lancet.* 2018;392:1036-1046. doi: 10.1016/S0140-6736(18)31924-X
61. Saito Y, et al. Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients with Type 2 Diabetes: 10-year Follow-up of a Randomized Controlled Trial. *Circulation.* 2016. doi: 10.1161/CIRCULATIONAHA.116.025760
62. Abdelaziz HK, et al. Aspirin for Primary Prevention of Cardiovascular Events. *J Am Coll Cardiol.* 2019;73:2915-2929. doi: 10.1016/j.jacc.2019.03.501
63. Zheng SL, et al. Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events: A Systematic Review and Meta-analysis. *JAMA.* 2019;321:277-287. doi: 10.1001/jama.2018.20578
64. Mahmoud AN, et al. Efficacy and safety of aspirin for primary prevention of cardiovascular events: a meta-analysis and trial sequential analysis of randomized controlled trials. *Eur Heart J.* 2019;40:607-617. doi: 10.1093/eurheartj/ehy813
65. Joseph P, et al. Polypill Therapy With and Without Aspirin to Prevent Cardiovascular Disease *Lancet.* 2021.
66. Arnett DK, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. *JACC.* 2019.
67. Force USPST, et al. Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement. *JAMA.* 2022;327:1577-1584. doi: 10.1001/jama.2022.4983
68. Cosentino F, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. *Eur Heart J.* 2019.
69. Visseren FLJ, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. *Eur Heart J.* 2021. doi: 10.1093/eurheartj/ehab484
70. Ajjan RA, et al. Antithrombotic therapy in diabetes: which, when, and for how long? *Eur Heart J.* 2021;42:2235-2259. doi: 10.1093/eurheartj/ehab128
71. Joseph JJ, et al. Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart Association. *Circulation.* 2022:CIR0000000000001040. doi: 10.1161/CIR.0000000000001040
72. Cainzos-Achirica M, et al. Coronary Artery Calcium for Personalized Allocation of Aspirin in Primary Prevention of Cardiovascular Disease in 2019: The MESA Study (Multi-Ethnic Study of Atherosclerosis). *Circulation.* 2020;141:1541-1553. doi: 10.1161/CIRCULATIONAHA.119.045010
73. Andreotti F, et al. Acute, periprocedural and longterm antithrombotic therapy in older adults. *Eur Heart J.* 2023;44:262-279. doi: 10.1093/eurheartj/ehac515
74. Loomans-Kropp HA, et al. Association of Aspirin Use With Mortality Risk Among Older Adult Participants in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. *JAMA Netw Open.* 2019;2:e1916729. doi: 10.1001/jamanetworkopen.2019.16729
75. Garcia Rodriguez LA, et al. Low-dose aspirin and risk of gastric and oesophageal cancer: a population-based study in the United Kingdom using The Health Improvement Network. *Int J Cancer.* 2020. doi: 10.1002/ijc.33022
76. Simon TG, et al. Association of Aspirin with Hepatocellular Carcinoma and Liver-Related Mortality. *N Engl J Med.* 2020;382:1018-1028. doi: 10.1056/NEJMoa1912035
77. Marquis-Gravel G, et al. Revisiting the Role of Aspirin for the Primary Prevention of Cardiovascular Disease. *Circulation.* 2019;140:1115-1124. doi: 10.1161/CIRCULATIONAHA.119.040205
78. Nordestgaard BG, et al. Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. *Eur Heart J.* 2016;37:1944-1958. doi: 10.1093/eurheartj/ehw152

79. Sajja A, et al. Discordance Between Standard Equations for Determination of LDL Cholesterol in Patients With Atherosclerosis. *J Am Coll Cardiol*. 2022;79:530-541. doi: 10.1016/j.jacc.2021.11.042
80. Nordestgaard BG. A Test in Context: Lipid Profile, Fasting Versus Nonfasting. *J Am Coll Cardiol*. 2017;70:1637-1646. doi: 10.1016/j.jacc.2017.08.006
81. Sathiyakumar V, et al. Fasting Versus Nonfasting and Low-Density Lipoprotein Cholesterol Accuracy. *Circulation*. 2018;137:10-19. doi: 10.1161/CIRCULATIONAHA.117.030677
82. Emerging Risk Factors C, et al. Lipid-related markers and cardiovascular disease prediction. *JAMA*. 2012;307:2499-2506. doi: 10.1001/jama.2012.6571
83. Natarajan P, et al. Polygenic Risk Score Identifies Subgroup With Higher Burden of Atherosclerosis and Greater Relative Benefit From Statin Therapy in the Primary Prevention Setting. *Circulation*. 2017;135:2091-2101. doi: 10.1161/CIRCULATIONAHA.116.024436
84. Ray KK, et al. Pharmacological lipid-modification therapies for prevention of ischaemic heart disease: current and future options. *Lancet*. 2019;394:697-708. doi: 10.1016/S0140-6736(19)31950-6
85. Kohli-Lynch CN, et al. Beyond Ten-Year Risk: A Cost-Effectiveness Analysis of Statins for the Primary Prevention of Cardiovascular Disease. *Circulation*. 2022. doi: 10.1161/CIRCULATIONAHA.121.057631
86. Shin S, et al. Impact of Intensive LDL Cholesterol Lowering on Coronary Artery Atherosclerosis Progression: A Serial CT Angiography Study. *JACC Cardiovascular imaging*. 2016. doi: 10.1016/j.jcmg.2016.04.013
87. Boekholdt SM, et al. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. *J Am Coll Cardiol*. 2014;64:485-494. doi: 10.1016/j.jacc.2014.02.615
88. Rodriguez F, et al. Association Between Intensity of Statin Therapy and Mortality in Patients With Atherosclerotic Cardiovascular Disease. *JAMA cardiology*. 2016. doi: 10.1001/jamacardio.2016.4052
89. Yusuf S, et al. Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. *N Engl J Med*. 2016;374:2021-2031. doi: 10.1056/NEJMoa1600176
90. Domanski MJ, et al. Time Course of LDL Cholesterol Exposure and Cardiovascular Disease Event Risk. *J Am Coll Cardiol*. 2020;76:1507-1516. doi: 10.1016/j.jacc.2020.07.059
91. Mach F, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. *Eur Heart J*. 2019.
92. Tsimikas S. Elevated lipoprotein(a) and the risk of stroke in children, young adults, and the elderly. *Eur Heart J*. 2021;42:2197-2200. doi: 10.1093/eurheartj/ehab251
93. Greco A, et al. Lipoprotein(a) as a Pharmacological Target: Premises, Promises, and Prospects. *Circulation*. 2025;151:400-415. doi: 10.1161/CIRCULATIONAHA.124.069210
94. Kronenberg F, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. *Eur Heart J*. 2022;43:3925-3946. doi: 10.1093/eurheartj/ehac361
95. Nordestgaard BG, et al. Lipoprotein(a) and cardiovascular disease. *Lancet*. 2024;404:1255-1264. doi: 10.1016/S0140-6736(24)01308-4
96. Khera AV, et al. Management of low levels of high-density lipoprotein-cholesterol. *Circulation*. 2013;128:72-78. doi: 10.1161/CIRCULATIONAHA.112.000443
97. Boden WE, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. *N Engl J Med*. 2011;365:2255-2267. doi: 10.1056/NEJMoa1107579
98. Group HTC, et al. Effects of extended-release niacin with laropirant in high-risk patients. *N Engl J Med*. 2014;371:203-212. doi: 10.1056/NEJMoa1300955
99. Schwartz GG, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. *N Engl J Med*. 2012;367:2089-2099. doi: 10.1056/NEJMoa1206797
100. Bytyci I, et al. Hydrophilic vs lipophilic statins in coronary artery disease: A meta-analysis of randomized controlled trials. *J Clin Lipidol*. 2017;11:624-637. doi: 10.1016/j.jacl.2017.03.003
101. Lee YC, et al. Discontinuation of statin therapy associates with Parkinson disease: a population-based study. *Neurology*. 2013;81:410-416. doi: 10.1212/WNL.0b013e31829d873c
102. Baudrand R, et al. Statin Use and Adrenal Aldosterone Production in Hypertensive and Diabetic Subjects. *Circulation*. 2015;132:1825-1833. doi: 10.1161/CIRCULATIONAHA.115.016759
103. Karlson BW, et al. Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGER. *Eur Heart J Cardiovasc Pharmacother*. 2016;2:212-217. doi: 10.1093/ehjcvp/pvw006
104. Stroes ES, et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. *Eur Heart J*. 2015;36:1012-1022. doi: 10.1093/eurheartj/ehv043
105. Thompson PD, et al. Statin-Associated Side Effects. *J Am Coll Cardiol*. 2016;67:2395-2410. doi: 10.1016/j.jacc.2016.02.071
106. Armitage J, et al. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. *Lancet*. 2010;376:1658-1669. doi: 10.1016/S0140-6736(10)60310-8
- S0140-6736(10)60310-8 [pii]
107. Lavie CJ, et al. Vitamin D and cardiovascular health. *Circulation*. 2013;128:2404-2406. doi: 10.1161/CIRCULATIONAHA.113.002902

108. Joy TR, et al. N-of-1 (single-patient) trials for statin-related myalgia. *Ann Intern Med.* 2014;160:301-310. doi: 10.7326/M13-1921
109. Gupta A, et al. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo Scandinavian Cardiac Outcomes Trial—Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. *The Lancet.* 2017. doi: 10.1016/S0140-6736(17)31075-9
110. Rosenson RS, et al. Optimizing Cholesterol Treatment in Patients With Muscle Complaints. *J Am Coll Cardiol.* 2017;70:1290-1301. doi: 10.1016/j.jacc.2017.07.752
111. Katzberg HD, et al. Assessment: symptomatic treatment for muscle cramps (an evidence-based review): report of the therapeutics and technology assessment subcommittee of the American academy of neurology. *Neurology.* 2010;74:691-696. doi: 10.1212/WNL.0b013e3181d0ccca
- 74/8/691 [pii]
112. Mammen AL. Statin-Associated Autoimmune Myopathy. *N Engl J Med.* 2016;374:664-669. doi: 10.1056/NEJMra1515161
113. Coste J, et al. Statins for primary prevention and rhabdomyolysis: A nationwide cohort study in France. *Eur J Prev Cardiol.* 2018;2047487318776831. doi: 10.1177/2047487318776831
114. Mach F, et al. Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. *Eur Heart J.* 2018;39:2526-2539. doi: 10.1093/eurheartj/ehy182
115. Russo MW, et al. Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network. *Hepatology.* 2014;60:679-686. doi: 10.1002/hep.27157
116. Swerdlow DI, et al. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. *Lancet.* 2015;385:351-361. doi: 10.1016/S0140-6736(14)61183-1
117. Mansi IA, et al. Association of Statin Therapy Initiation With Diabetes Progression: A Retrospective Matched-Cohort Study. *JAMA Intern Med.* 2021. doi: 10.1001/jamainternmed.2021.5714
118. Besseling J, et al. Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus. *JAMA.* 2015;313:1029-1036. doi: 10.1001/jama.2015.1206
119. Vallejo-Vaz AJ, et al. Effect of pitavastatin on glucose, HbA1c and incident diabetes: A meta-analysis of randomized controlled clinical trials in individuals without diabetes. *Atherosclerosis.* 2015;241:409-418. doi: 10.1016/j.atherosclerosis.2015.06.001
120. Lee YJ, et al. Rosuvastatin versus atorvastatin treatment in adults with coronary artery disease: secondary analysis of the randomised LODESTAR trial. *BMJ.* 2023;383:e075837. doi: 10.1136/bmj-2023-075837
121. Samaras K, et al. Effects of Statins on Memory, Cognition, and Brain Volume in the Elderly. *JACC.* 2019.
122. Dormuth CR, et al. Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases. *BMJ.* 2013;346:f880. doi: 10.1136/bmj.f880
123. Bangalore S, et al. Statin and the risk of renal-related serious adverse events: Analysis from the IDEAL, TNT, CARDS, ASPEN, SPARCL, and other placebo-controlled trials. *Am J Cardiol.* 2014;113:2018-2020. doi: 10.1016/j.amjcard.2014.03.046
124. Naci H, et al. Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials. *Circulation Cardiovascular quality and outcomes.* 2013;6:390-399. doi: 10.1161/CIRCOUTCOMES.111.000071
125. Frohlich GM, et al. Statins and the risk of cancer after heart transplantation. *Circulation.* 2012;126:440-447. doi: 10.1161/CIRCULATIONAHA.111.081059
- CIRCULATIONAHA.111.081059 [pii]
126. Kernan WN, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke.* 2014;45:2160-2236. doi: 10.1161/STR.0000000000000024
127. Westover MB, et al. Statin use following intracerebral hemorrhage: a decision analysis. *Arch Neurol.* 2011;68:573-579. doi: 10.1001/archneurol.2010.356
- archneurol.2010.356 [pii]
128. Golomb BA, et al. Effects of statins on energy and fatigue with exertion: results from a randomized controlled trial. *Arch Intern Med.* 2012;172:1180-1182. doi: 10.1001/archinternmed.2012.2171
- 1182551 [pii]
129. Bytci I, et al. Prevalence of statin intolerance: a meta-analysis. *Eur Heart J.* 2022;43:3213-3223. doi: 10.1093/eurheartj/ehac015
130. Mortensen MB, et al. Elevated LDL cholesterol and increased risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals aged 70-100 years: a contemporary primary prevention cohort. *Lancet.* 2020;396:1644-1652. doi: 10.1016/S0140-6736(20)32233-9
131. Gencer B, et al. Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. *Lancet.* 2020;396:1637-1643. doi: 10.1016/S0140-6736(20)32332-1
132. Zhou Z, et al. Effect of Statin Therapy on Cognitive Decline and Incident Dementia in Older Adults. *JACC.* 2021.

133. Xu W, et al. Benefits and Risks Associated With Statin Therapy for Primary Prevention in Old and Very Old Adults : Real-World Evidence From a Target Trial Emulation Study. *Ann Intern Med*. 2024;177:701-710. doi: 10.7326/M24-0004
134. Zoungas S, et al. Atorvastatin, Cardiovascular Events, and Disability-free Survival in Older Adults. *NEJM*. 2026.
135. Christensen JJ, et al. Statin use in pregnancy and risk of congenital malformations: a Norwegian nationwide study. *Eur Heart J*. 2026;47:318-327. doi: 10.1093/eurheartj/ehaf592
136. Wiggins BS, et al. Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association. *Circulation*. 2016;134:e468-e495. doi: CIR.0000000000000456 [pii]
- 10.1161/CIR.0000000000000456
137. Writing C, et al. 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statins Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. *J Am Coll Cardiol*. 2016;68:92-125. doi: 10.1016/j.jacc.2016.03.519
138. Myocardial Infarction Genetics Consortium I, et al. Inactivating mutations in NPC1L1 and protection from coronary heart disease. *N Engl J Med*. 2014;371:2072-2082. doi: 10.1056/NEJMoa1405386
139. Tsujita K, et al. Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention: The Multicenter Randomized Controlled PRECISE-IVUS Trial. *J Am Coll Cardiol*. 2015;66:495-507. doi: 10.1016/j.jacc.2015.05.065
140. Cannon CP, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. *N Engl J Med*. 2015;372:2387-2397. doi: 10.1056/NEJMoa1410489
141. Bohula EA, et al. Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients with Acute Coronary Syndrome in IMPROVE-IT. *Circulation*. 2017. doi: 10.1161/CIRCULATIONAHA.117.029095
142. Eisen A, et al. The benefit of adding ezetimibe to statin therapy in patients with prior coronary artery bypass graft surgery and acute coronary syndrome in the IMPROVE-IT trial. *Eur Heart J*. 2016. doi: 10.1093/eurheartj/ehw377
143. Ouchi Y, et al. Ezetimibe Lipid-Lowering Trial on Prevention of Atherosclerotic Cardiovascular Disease in 75 or Older (EWTOPIA 75): A Randomized, Controlled Trial. *Circulation*. 2019;140:992-1003. doi: 10.1161/CIRCULATIONAHA.118.039415
144. Ginsberg HN, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. *N Engl J Med*. 2010;362:1563-1574. doi: 10.1056/NEJMoa1001282
- NEJMoa1001282 [pii]
145. Das Pradhan A, et al. Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk. *N Engl J Med*. 2022;387:1923-1934. doi: 10.1056/NEJMoa2210645
146. Miller M, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. *Circulation*. 2011;123:2292-2333. doi: 10.1161/CIR.0b013e3182160726
- CIR.0b013e3182160726 [pii]
147. Jun M, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. *Lancet*. 2010;375:1875-1884. doi: 10.1016/S0140-6736(10)60656-3
- S0140-6736(10)60656-3 [pii]
148. Laufs U, et al. Clinical review on triglycerides. *Eur Heart J*. 2020;41:99-109c. doi: 10.1093/eurheartj/ehz785
149. Skulas-Ray AC, et al. Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association. *Circulation*. 2019;140:e673-e691. doi: 10.1161/CIR.0000000000000709
150. Aung T, et al. Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks. Meta-analysis of 10 Trials Involving 77 917 Individuals. *JAMA Cardiol*. 2018. doi: 10.1001/jamacardio.2017.5205
151. Group ASC. Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus. *N Engl J Med*. 2018. doi: 10.1056/NEJMoa1804989
152. Manson JE, et al. Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer. *N Engl J Med*. 2019;380:23-32. doi: 10.1056/NEJMoa1811403
153. Nicholls SJ, et al. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. *JAMA*. 2020. doi: 10.1001/jama.2020.22258
154. Kalstad AA, et al. Effects of n-3 Fatty Acid Supplements in Elderly Patients After Myocardial Infarction: A Randomized, Controlled Trial. *Circulation*. 2021;143:528-539. doi: 10.1161/CIRCULATIONAHA.120.052209
155. Bhatt DL, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. *N Engl J Med*. 2019;380:11-22. doi: 10.1056/NEJMoa1812792
156. Szarek M, et al. Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl. *J Am Coll Cardiol*. 2024;83:1529-1539. doi: 10.1016/j.jacc.2024.02.016

157. Budoff MJ, et al. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial. *Eur Heart J*. 2020;41:3925-3932. doi: 10.1093/eurheartj/ehaa652
158. Verma S, et al. Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG. *Circulation*. 2021;144:1845-1855. doi: 10.1161/CIRCULATIONAHA.121.056290
159. Marston NA, et al. Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials. *Circulation*. 2019;140:1308-1317. doi: 10.1161/CIRCULATIONAHA.119.041998
160. Doi T, et al. A possible explanation for the contrasting results of REDUCE-IT vs. STRENGTH: cohort study mimicking trial designs. *Eur Heart J*. 2021;42:4807-4817. doi: 10.1093/eurheartj/ehab555
161. Miyauchi K, et al. Randomized Trial for Evaluation in Secondary Prevention Efficacy of Combination Therapy-Statins and Eicosapentaenoic Acid (RESPECT-EPA). *Circulation*. 2024;150:425-434. doi: 10.1161/CIRCULATIONAHA.123.065520
162. Weinberg RL, et al. Cardiovascular Impact of Nutritional Supplementation With Omega-3 Fatty Acids. *JACC*. 2021.
163. Gencer B, et al. Effect of Long-Term Marine Omega-3 Fatty Acids Supplementation on the Risk of Atrial Fibrillation in Randomized Controlled Trials of Cardiovascular Outcomes: A Systematic Review and Meta-Analysis. *Circulation*. 2021. doi: 10.1161/CIRCULATIONAHA.121.055654
164. Marcus MD, et al. Omega-3 Fatty Acids and Arrhythmias. *Circulation*. 2024;150:488-503. doi: 10.1161/CIRCULATIONAHA.123.065769
165. Schwartz GG, et al. Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol. *J Am Coll Cardiol*. 2021;78:421-433. doi: 10.1016/j.jacc.2021.04.102
166. O'Donoghue ML, et al. Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease. *Circulation*. 2022;146:1109-1119. doi: 10.1161/CIRCULATIONAHA.122.061620
167. Raber L, et al. Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial. *JAMA*. 2022;327:1771-1781. doi: 10.1001/jama.2022.5218
168. Perez de Isla L, et al. Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients with Familial Hypercholesterolemia: The ARCHITECT Study. *Circulation*. 2023;147:1436-1443. doi: 10.1161/CIRCULATIONAHA.122.062557
169. Lee S-J, et al. Therapy for Atrial Fibrillation in Patients with Drug-Eluting Stents. *NEJM*. 2025.
170. Colhoun HM, et al. No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies. *Eur Heart J*. 2016;37:2981-2989. doi: 10.1093/eurheartj/ehw292
171. Khan AR, et al. Increased Risk of Adverse Neurocognitive Outcomes With Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors. *Circulation Cardiovascular quality and outcomes*. 2017;10. doi: 10.1161/CIRCOUTCOMES.116.003153
172. Robinson JG, et al. Safety of Very Low Low-Density Lipoprotein Cholesterol Levels With Alirocumab: Pooled Data From Randomized Trials. *J Am Coll Cardiol*. 2017;69:471-482. doi: 10.1016/j.jacc.2016.11.037
173. Giugliano RP, et al. Cognitive Function in a Randomized Trial of Evolocumab. *N Engl J Med*. 2017;377:633-643. doi: 10.1056/NEJMoa1701131
174. Ridker PM, et al. Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. *N Engl J Med*. 2017;376:1527-1539. doi: 10.1056/NEJMoa1701488
175. Roth EM, et al. Antidrug Antibodies in Patients Treated with Alirocumab. *N Engl J Med*. 2017;376:1589-1590. doi: 10.1056/NEJMc1616623
176. Ray KK, et al. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. *N Engl J Med*. 2020. doi: 10.1056/NEJMoa1912387
177. Raal FJ, et al. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. *N Engl J Med*. 2020. doi: 10.1056/NEJMoa1913805
178. 2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statins Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk. *J Am Coll Cardiol*. 2017. doi: 10.1016/j.jacc.2017.07.745
179. Landmesser U, et al. 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia. *Eur Heart J*. 2017. doi: 10.1093/eurheartj/ehx549
180. Ray KK, et al. Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol. *N Engl J Med*. 2017;376:1430-1440. doi: 10.1056/NEJMoa1615758
181. Ballantyne CM, et al. Efficacy and Safety of Oral PCSK9 Inhibitor Enlicotide in Adults With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial. *JAMA*. 2026;335:129-139. doi: 10.1001/jama.2025.20620
182. Catapano AL, et al. Oral PCSK9 Inhibitor Enlicotide versus Oral Non-statin Therapies: A Phase 3 Randomized Clinical Trial *JACC*. 2026.

183. Vega RB, et al. Laroprovstat, the First Oral Small-Molecule PCSK9 Inhibitor for the Treatment of Hypercholesterolemia: Results From a Randomized, Single-Blind, Placebo-Controlled Phase 1 Trial in Treatment-Naïve Patients. *Circulation*. 2026;153:1999-2010. doi: 10.1161/CIRCULATIONAHA.125.075973
184. Wiegman A, et al. Efficacy and Safety of Inclisiran in Adolescents With Genetically Confirmed Homozygous Familial Hypercholesterolemia: Results From the Double-Blind, Placebo-Controlled Part of the ORION-13 Randomized Trial. *Circulation*. 2025;151:1758-1766. doi: 10.1161/CIRCULATIONAHA.124.073233
185. Koren MJ, et al. An "Inclisiran First" Strategy vs Usual Care in Patients With Atherosclerotic Cardiovascular Disease. *J Am Coll Cardiol*. 2024;83:1939-1952. doi: 10.1016/j.jacc.2024.03.382
186. Raal F, et al. Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial. *Circulation*. 2024;149:354-362. doi: 10.1161/CIRCULATIONAHA.122.063460
187. Damase TR, et al. Established and Emerging Nucleic Acid Therapies for Familial Hypercholesterolemia. *Circulation*. 2024;150:724-735. doi: 10.1161/CIRCULATIONAHA.123.067957
188. Bergmark BA, et al. Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia. *N Engl J Med*. 2025. doi: 10.1056/NEJMoa2507227
189. Marston NA, et al. Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk. *NEJM*. 2025.
190. Ference BA, et al. Mendelian Randomization Study of ACLY and Cardiovascular Disease. *N Engl J Med*. 2019;380:1033-1042. doi: 10.1056/NEJMoa1806747
191. Nissen SE, et al. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. *N Engl J Med*. 2023;388:1353-1364. doi: 10.1056/NEJMoa2215024
192. Ray KK, et al. Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol. *N Engl J Med*. 2019;380:1022-1032. doi: 10.1056/NEJMoa1803917
193. Raposeiras-Roubin S, et al. Triple Versus Dual Lipid-Lowering Therapy in Acute Coronary Syndrome: The ES-BempedACS Randomized Clinical Trial. *Circulation*. 2026;153:140-149. doi: 10.1161/CIRCULATIONAHA.125.075388
194. Zhong W, et al. Efficacy and Safety of Quarterly Dosing SHR-1918 in Patients With Suboptimally Controlled Hyperlipidemia. *JACC*. 2026.
195. Group HTRC. Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. *N Engl J Med*. 2017. doi: 10.1056/NEJMoa1706444
196. Nicholls SJ, et al. Obicetrapib and lipoprotein(a) levels in patients at high cardiovascular risk: a pooled analysis of trials. *Eur Heart J*. 2026;47:3404-3414. doi: 10.1093/eurheartj/ehag399
197. Damask A, et al. Patients With High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit From Alirocumab Treatment in the ODYSSEY OUTCOMES Trial. *Circulation*. 2020;141:624-636. doi: 10.1161/CIRCULATIONAHA.119.044434
198. Marston NA, et al. Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score: Results From the FOURIER Trial. *Circulation*. 2020;141:616-623. doi: 10.1161/CIRCULATIONAHA.119.043805
199. Raal FJ, et al. Evinacumab for Homozygous Familial Hypercholesterolemia. *N Engl J Med*. 2020;383:711-720. doi: 10.1056/NEJMoa2004215
200. Inzucchi SE, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetologia*. 2012;55:1577-1596. doi: 10.1007/s00125-012-2534-0
201. Kalyani RR. Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes. *N Engl J Med*. 2021;384:1248-1260. doi: 10.1056/NEJMcp2000280
202. Das SR, et al. 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee. *J Am Coll Cardiol*. 2020;76:1117-1145. doi: 10.1016/j.jacc.2020.05.037
203. Arnold SV, et al. Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association. *Circulation*. 2020;141:e779-e806. doi: 10.1161/CIR.0000000000000766
204. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J*. 2021.
205. Brown E, et al. SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. *Lancet*. 2021. doi: 10.1016/S0140-6736(21)00536-5
206. Holman RR, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. *N Engl J Med*. 2008;359:1577-1589. doi: 10.1056/NEJMoa0806470
207. Qaseem A, et al. Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline Update From the American College of Physicians. *Ann Intern Med*. 2017;166:279-290. doi: 10.7326/M16-1860
208. Bjornstad P, et al. Metformin Improves Insulin Sensitivity and Vascular Health in Youth With Type 1 Diabetes Mellitus. *Circulation*. 2018;138:2895-2907. doi: 10.1161/CIRCULATIONAHA.118.035525
209. Wilcox T, et al. Diabetic Agents, From Metformin to SGLT2 Inhibitors and GLP1 Receptor Agonists. *JACC*. 2020. doi: 10.1016/j.jacc.2020.02.056

210. Rena G, et al. Repurposing Metformin for Cardiovascular Disease. *Circulation*. 2018. doi: 10.1161/CIRCULATIONAHA.117.031735
211. Bergmark BA, et al. Metformin Use and Clinical Outcomes Among Patients With Diabetes Mellitus With or Without Heart Failure or Kidney Dysfunction: Observations From the SAVOR-TIMI 53 Trial. *Circulation*. 2019;140:1004-1014. doi: 10.1161/CIRCULATIONAHA.119.040144
212. Niessner A, et al. Non-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. *Eur Heart J*. 2018;39:2274-2281. doi: 10.1093/eurheartj/ehx625
213. Furtado RHM, et al. Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction. *Circulation*. 2019;139:2516-2527. doi: 10.1161/CIRCULATIONAHA.119.039996
214. Kato ET, et al. Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. *Circulation*. 2019;139:2528-2536. doi: 10.1161/CIRCULATIONAHA.119.040130
215. Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups. *Circulation*. 2019;140:739-750. doi: 10.1161/CIRCULATIONAHA.119.042007
216. McMurray JJV, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. *N Engl J Med*. 2019;381:1995-2008. doi: 10.1056/NEJMoa1911303
217. Packer M, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. *N Engl J Med*. 2020. doi: 10.1056/NEJMoa2022190
218. Cannon CP, et al. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. *N Engl J Med*. 2020;383:1425-1435. doi: 10.1056/NEJMoa2004967
219. Bhatt DL, et al. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. *N Engl J Med*. 2021;384:117-128. doi: 10.1056/NEJMoa2030183
220. Zelniker TA, et al. Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial. *Circulation*. 2020;141:1227-1234. doi: 10.1161/CIRCULATIONAHA.119.044183
221. Pocock SJ, et al. Statistical Appraisal of 6 Recent Clinical Trials in Cardiology: JACC State-of-the-Art Review. *J Am Coll Cardiol*. 2019;73:2740-2755. doi: 10.1016/j.jacc.2019.03.484
222. Cherney DZ, et al. Use of Sodium Glucose Cotransporter 2 Inhibitors in the Hands of Cardiologists: With Great Power Comes Great Responsibility. *Circulation*. 2016;134:1915-1917. doi: 10.1161/CIRCULATIONAHA.116.024764
223. Mahaffey KW, et al. Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). *Circulation*. 2017. doi: 10.1161/CIRCULATIONAHA.117.032038
224. Bersoff-Matcha SJ, et al. Fournier Gangrene Associated With Sodium-Glucose Cotransporter-2 Inhibitors: A Review of Spontaneous Postmarketing Cases. *Ann Intern Med*. 2019;170:764-769. doi: 10.7326/M19-0085
225. Pitt B, et al. Does SGLT1 Inhibition Add Benefit to SGLT2 Inhibition in Type 2 Diabetes? *Circulation*. 2021;144:4-6. doi: 10.1161/CIRCULATIONAHA.121.054442
226. Nauck MA, et al. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors. *Circulation*. 2017;136:849-870. doi: 10.1161/CIRCULATIONAHA.117.028136
227. Waldrop G, et al. Incretin-Based Therapy for Diabetes: What a Cardiologist Needs to Know. *J Am Coll Cardiol*. 2016;67:1488-1496. doi: 10.1016/j.jacc.2015.12.058
228. Jia X, et al. GLP-1 Receptor Agonists and Cardiovascular Disease: a Meta-Analysis of Recent Cardiac Outcome Trials. *Cardiovasc Drugs Ther*. 2018;32:65-72. doi: 10.1007/s10557-018-6773-2
229. Shaman AM, et al. Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER. *Circulation*. 2022;145:575-585. doi: 10.1161/CIRCULATIONAHA.121.055459
230. Marso SP, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. *N Engl J Med*. 2016;375:311-322. doi: 10.1056/NEJMoa1603827
231. Group GSR, et al. Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes. *N Engl J Med*. 2022;387:1075-1088. doi: 10.1056/NEJMoa2200436
232. Green JB, et al. Cardiovascular Outcomes in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study). *Circulation*. 2024. doi: 10.1161/CIRCULATIONAHA.123.066604
233. Packer M, et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. *N Engl J Med*. 2025;392:427-437. doi: 10.1056/NEJMoa2410027
234. Khan MS, et al. Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization. *Circulation*. 2020;142:1205-1218. doi: 10.1161/CIRCULATIONAHA.120.045888
235. Marso SP, et al. Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure. *JACC*. 2020.
236. Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. *NEJM*. 2023.
237. Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. *N Engl J Med*. 2025;393:26-36. doi: 10.1056/NEJMoa2416394

238. Sattar N, et al. Novel diabetes drugs and the cardiovascular specialist. *J Am Coll Cardiol*. 2017;69:264-256.
239. Gerstein HC, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. *The Lancet*. 2019. doi: 10.1016/S0140-6736(19)31149-3
240. McGuire DK, et al. Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial. *JAMA cardiology*. 2016;1:126-135. doi: 10.1001/jamacardio.2016.0103
241. Fadini GP, et al. Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB Database. *Eur Heart J*. 2015;36:2454-2462. doi: 10.1093/eurheartj/ehv301
242. Xu Y, et al. Risk of Heart Failure Hospitalization for GLP-1 Receptor Agonists Versus DPP-4 Inhibitors or SGLT-2 Inhibitors in Patients With Type 2 Diabetes: A Target Trial Emulation. *Circulation*. 2026;153:1086-1100. doi: 10.1161/CIRCULATIONAHA.125.075157
243. Gerstein HC, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. *N Engl J Med*. 2012;367:319-328. doi: 10.1056/NEJMoa1203858
244. Simpson SH, et al. Mortality risk among sulfonylureas: a systematic review and network meta-analysis. *The lancet Diabetes & endocrinology*. 2015;3:43-51. doi: 10.1016/S2213-8587(14)70213-X
245. Loke YK, et al. Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. *BMJ*. 2011;342:d1309. doi: 10.1136/bmj.d1309
bmj.d1309 [pii]
246. Graham DJ, et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. *JAMA*. 2010;304:411-418. doi: 10.1001/jama.2010.920
jama.2010.920 [pii]
247. Nicholls SJ, et al. Lowering the triglyceride/high-density lipoprotein cholesterol ratio is associated with the beneficial impact of pioglitazone on progression of coronary atherosclerosis in diabetic patients: insights from the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) study. *J Am Coll Cardiol*. 2011;57:153-159. doi: 10.1016/j.jacc.2010.06.055
S0735-1097(10)04304-4 [pii]
248. Young LH, et al. Cardiac Outcomes After Ischemic Stroke or TIA: Effects of Pioglitazone in Patients with Insulin Resistance Without Diabetes. *Circulation*. 2017. doi: 10.1161/CIRCULATIONAHA.116.024863
249. Li Z, et al. Association between pioglitazone use and the risk of bladder cancer among subjects with diabetes mellitus: a dose-response meta-analysis. *Int J Clin Pharmacol Ther*. 2017;55:210-219. doi: 10.5414/CP202670
250. Levin D, et al. Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. *Diabetologia*. 2015;58:493-504. doi: 10.1007/s00125-014-3456-9
251. Nissen SE, et al. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. *Arch Intern Med*. 2010;170:1191-1201. doi: 10.1001/archinternmed.2010.207
2010.207 [pii]
252. Bach RG, et al. Rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. *Circulation*. 2013;128:785-794. doi: 10.1161/CIRCULATIONAHA.112.000678
CIRCULATIONAHA.112.000678 [pii]
253. Holman RR, et al. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. *Lancet Diabetes Endocrinol*. 2017. doi: 10.1016/S2213-8587(17)30309-1
254. Damman K, et al. 2026 ESC Guidelines for the management of cardiovascular disease and chronic kidney disease, in collaboration with the European Renal Association (ERA). *Eur Heart J*. 2026. doi: 10.1093/eurheartj/ehag098